BRAF and benign thyroid gland neoplasm: The has-miR-200a-5p as an overexpressed molecule is a sensitive biomarker and could be combined with immunohistochemical markers such as TPO, CD56, Galectin 3, MC, CK19, and BRAF both to detect and to distinguish between PTC and benign thyroid tumor with papillary hyperplasia (52).